Vascular Closure Devices Global Market – Forecast To 2022

1 EXECUTIVE SUMMARY 15

2 INTRODUCTION 21

• 2.1 KEY TAKE AWAYS 21
• 2.2 REPORT DESCRIPTION 21
• 2.3 MARKETS COVERED 23
• 2.4 STAKEHOLDERS 24
• 2.5 RESEARCH METHODOLOGY 24
  • 2.5.1 MARKET SIZE ESTIMATION 25
  • 2.5.2 MARKET CRACKDOWN AND DATA TRIANGULATION 28
  • 2.5.3 SECONDARY SOURCES 29
  • 2.5.4 PRIMARY SOURCES 30
  • 2.5.5 KEY DATA POINTS FROM SECONDARY SOURCES 30
  • 2.5.6 KEY DATA POINTS FROM PRIMARY SOURCES 31
  • 2.5.7 ASSUMPTIONS 31

3 MARKET ANALYSIS 33

• 3.1 INTRODUCTION 33
• 3.2 MARKET SEGMENTATION 34
• 3.3 FACTORS INFLUENCING MARKET 36
  • 3.3.1 DRIVERS AND OPPORTUNITIES 36
    • 3.3.1.1 Increasing catheterization related procedures 36
    • 3.3.1.2 Preference for minimally-invasive solutions 37
    • 3.3.1.3 Ease in usage and quick hemostatic properties of VCDs 38
    • 3.3.1.4 Increased utilization of transradial arterial access 38
  • 3.3.2 RESTRAINTS AND THREATS 39
    • 3.3.2.1 High price of products 39
    • 3.3.2.2 Complications associated with VCD 39
    • 3.3.2.3 Less adoption of novel technologies in emerging countries 40
    • 3.3.2.4 Reduced reimbursement 40
    • 3.3.2.5 Usage of animal related sources 41
    • 3.3.2.6 Lower revenue potential of VCD 41
• 3.4 PORTER’S FIVE FORCE ANALYSIS 41
  • 3.4.1 THREAT OF NEW ENTRANTS 42
  • 3.4.2 THREAT OF SUBSTITUTES 42
  • 3.4.3 BARGAINING POWER OF SUPPLIERS 44
  • 3.4.4 BARGAINING POWER OF BUYERS 44
  • 3.4.5 COMPETITIVE RIVALRY 44
• 3.5 REGULATORY AFFAIRS 45
  • 3.5.1 U.S. 45
  • 3.5.2 EUROPE 46
  • 3.5.3 INDIA 46
  • 3.5.4 CHINA 47
  • 3.5.5 JAPAN 48
• 3.6 REIMBURSEMENT SCENARIO 49
  • 3.6.1 TRANSCATHETER EMBOLIZATION OR OCCLUSION SERVICES 49
  • 3.6.2 THROMBOLYSIS 51
  • 3.6.3 DIAGNOSTIC CARDIAC CATHETERIZATION 51
  • 3.6.4 INJECTION DIAGNOSTIC CARDIAC CATHETERIZATION 56
• 3.7 UPCOMING TECHNOLOGIES 58
• 3.8 SUPPLY CHAIN ANALYSIS 58
• 3.9 MARKET SHARE ANALYSIS BY MAJOR PLAYERS 60
• 3.10 PATENT TRENDS 62

4 VASCULAR CLOSURE DEVICES GLOBAL MARKET, BY TYPE 64

• 4.1 INTRODUCTION 64
• 4.2 ACTIVE APPROXIMATORS 66
  • 4.2.1 CLIPS 70
  • 4.2.2 SUTURE MEDIATED DEVICES 72
  • 4.2.3 PLUGS 73
    • 4.2.3.1 Collagen based 75
    • 4.2.3.2 Polymer based 76
    • 4.2.3.3 FISH 78
• 4.3 PASSIVE APPROXIMATORS 79
  • 4.3.1 HEMOSTATIC PADS/PATCHES 82
  • 4.3.2 COMPRESSION DEVICES 84

5 VASCULAR CLOSURE DEVICES GLOBAL MARKET, BY INTERVENTION 86

• 5.1 INTRODUCTION 86
• 5.2 DIGNOSTICS 88
• 5.3 THERAPEUTICS 90

6 VASCULAR CLOSURE DEVICES GLOBAL MARKET, BY ACCESS 93

• 6.1 INTRODUCTION 93
• 6.2 FEMORAL ACCESS 95
• 6.3 RADIAL ACCESS 97

7 VASCULAR CLOSURE DEVICES GLOBAL MARKET, BY GEOGRAPHY 101

• 7.1 INTRODUCTION 101
• 7.2 NORTH AMERICA 102
• 7.3 EUROPE 108
• 7.4 ASIA PACIFIC 114
• 7.5 REST OF THE WORLD 119

8 COMPANY DEVELOPMENTS 126

• 8.1 INTRODUCTION 126
• 8.2 ACQUISITION AS A MAJOR GROWTH STRATEGY OF ACTIVE PHARMACEUTICAL INGREDIENTS MARKET PLAYERS 127
• 8.3 MERGERS AND ACQUISITION 127
• 8.4 AGREEMENTS PARTERNER SHIPS, COLLABORATIONS & JOINT VENTURES 131
• 8.5 APPROVALS 134
• 8.6 BUSINESS EXPANSION 137
• 8.7 NEW PRODUCT LAUNCH 139

9 COMPANY PROFILES 141

• 9.1 ABBOTT LABORATORIES 141
  • 9.1.1 OVERVIEW 141
  • 9.1.2 FINANCIALS 142
  • 9.1.3 PRODUCT PORTFOLIO 144
  • 9.1.4 KEY DEVELOPMENTS 145
  • 9.1.5 BUSINESS STRATEGY 146
  • 9.1.6 SWOT ANALYSIS 147
• 9.2 ADVANCED VASCULAR DYNAMICS 148
  • 9.2.1 OVERVIEW 148
  • 9.2.2 FINANCIALS 148
  • 9.2.3 PRODUCT PORTFOLIO 148
  • 9.2.4 KEY DEVELOPMENTS 149
  • 9.2.5 BUSINESS STRATEGY 149
  • 9.2.6 SWOT ANALYSIS 150
• 9.3 B. BRAUN MELSUNGEN AG 151
  • 9.3.1 OVERVIEW 151
  • 9.3.2 FINANCIALS 152
  • 9.3.3 PRODUCT PORTFOLIO 154
  • 9.3.4 KEY DEVELOPMENTS 155
  • 9.3.5 BUSINESS STRATEGY 156
  • 9.3.6 SWOT ANALYSIS 157
• 9.4 BIOTRONIK SE & CO. KG 158
  • 9.4.1 OVERVIEW 158
  • 9.4.2 FINANCIALS 158
  • 9.4.3 PRODUCT PORTFOLIO 158
  • 9.4.4 KEY DEVELOPMENTS 159
  • 9.4.5 BUSINESS STRATEGY 159
  • 9.4.6 SWOT ANALYSIS 160
• 9.5 C.R.BARD INC. 161
  • 9.5.1 OVERVIEW 161
  • 9.5.2 FINANCIALS 162
  • 9.5.3 PRODUCT PORTFOLIO 164
  • 9.5.4 KEY DEVELOPMENTS 165
  • 9.5.5 BUSINESS STRATEGY 166
  • 9.5.6 SWOT ANALYSIS 167
• 9.6 CARDINAL HEALTH INC. 168
  • 9.6.1 OVERVIEW 168
  • 9.6.2 FINANCIALS 169
  • 9.6.3 PRODUCT PORTFOLIO 171
  • 9.6.4 KEY DEVELOPMENTS 172
  • 9.6.5 BUSINESS STRATEGY 174
  • 9.6.6 SWOT ANALYSIS 175
• 9.7 CARDIVA MEDICALS, INC. 176
  • 9.7.1 OVERVIEW 176
  • 9.7.2 FINANCIALS 176
  • 9.7.3 PRODUCT PORTFOLIO 176
  • 9.7.4 KEY DEVELOPMENTS 177
  • 9.7.5 BUSINESS STRATEGY 177
  • 9.7.6 SWOT ANALYSIS 178
• 9.8 MORRIS INNOVATIVE, INC. 179
  • 9.8.1 OVERVIEW 179
  • 9.8.2 FINANCIALS 179
  • 9.8.3 PRODUCT PORTFOLIO 179
  • 9.8.4 KEY DEVELOPMENTS 180
  • 9.8.5 BUSINESS STRATEGY 180
  • 9.8.6 SWOT ANALYSIS 181
• 9.9 SCION BIOMEDICALS, INC. 182
  • 9.9.1 OVERVIEW 182
  • 9.9.2 FINANCIALS 182
  • 9.9.3 PRODUCT PORTFOLIO 182
  • 9.9.4 KEY DEVELOPMENTS 183
  • 9.9.5 BUSINESS STRATEGY 183
  • 9.9.6 SWOT ANALYSIS 184
• 9.10 ST.JUDE MEDICAL 185
  • 9.10.1 OVERVIEW 185
  • 9.10.2 FINANCIALS 186
  • 9.10.3 PRODUCT PORTFOLIO 188
  • 9.10.4 KEY DEVELOPMENTS 189
  • 9.10.5 BUSINESS STRATEGY 190
  • 9.10.6 SWOT ANALYSIS 191
• 9.11 TERUMO CORPORATION 192
  • 9.11.1 OVERVIEW 192
  • 9.11.2 FINANCIALS 193
  • 9.11.3 PRODUCT PORTFOLIO 195
  • 9.11.4 KEY DEVELOPMENTS 196
  • 9.11.5 BUSINESS STRATEGY 197
  • 9.11.6 SWOT ANALYSIS 199
• 9.12 VASCULAR SOLUTIONS INC. 200
  • 9.12.1 OVERVIEW 200
  • 9.12.2 FINANCIALS 200
  • 9.12.3 PRODUCT PORTFOLIO 202
  • 9.12.4 KEY DEVELOPMENTS 203
  • 9.12.5 BUSINESS STRATEGY 203
  • 9.12.6 SWOT ANALYSIS 204

LIST OF TABLES

TABLE 1 VASCULAR CLOSURE DEVICES GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN) 18

TABLE 2 VASCULAR CLOSURE DEVICES GLOBAL MARKET REVENUE, BY TYPE,

(2014-2022) ($MN) 18

TABLE 3 VASCULAR CLOSURE DEVICES GLOBAL MARKET REVENUE,

BY INTERVENTION, (2014-2022) ($MN) 19

TABLE 4 VASCULAR CLOSURE DEVICES GLOBAL MARKET REVENUE, BY ACCESS, (2014-2022) ($MN) 20

TABLE 5 VASCULAR CLOSURE DEVICES GLOBAL MARKET REVENUE, BY TYPE,

(2014-2022) ($MN) 66

TABLE 6 ACTIVE APPROXIMATOR GLOBAL MARKET REVENUE, BY REGION,

(2014-2022) ($MN) 69

TABLE 7 ACTIVE APPROXIMATOR GLOBAL MARKET REVENUE, BY PRODUCT,

(2015-2022) ($MN) 70

TABLE 8 CLIPS GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN) 71

TABLE 9 SUTURE MEDIATED DEVICES GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN) 73

TABLE 10 PLUGS GLOBAL MARKET REVENUE, BY MATERIAL, (2014-2022) ($MN) 74

TABLE 11 PLUGS GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN) 75

TABLE 12 COLLAGEN BASED PLUGS GLOBAL MARKET REVENUE, BY REGION,

(2014-2022) ($MN) 76

TABLE 13 POLYMER BASED PLUGS GLOBAL MARKET REVENUE, BY REGION,

(2014-2022) ($MN) 78

TABLE 14 PASSIVE APPROXIMATOR GLOBAL MARKET REVENUE, BY PRODUCT,

(2014-2022) ($MN) 81

TABLE 15 PASSIVE APPROXIMATOR GLOBAL MARKET REVENUE, BY REGION,

(2014-2022) ($MN) 82

TABLE 16 HEMOSTATIC PADS/PATCHES GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN) 84

TABLE 17 COMPRESSION DEVICES GLOBAL MARKET REVENUE, BY REGION,

(2014-2022) ($MN) 85

TABLE 18 VASCULAR CLOSURE DEVICES GLOBAL MARKET REVENUE,

BY INTERVENTION, (2014-2022) ($MN) 88

TABLE 19 DIAGNOSTICS VASCULAR CLOSURE DEVICES GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN) 90

TABLE 20 THERAPEUTICS VASCULAR CLOSURE GLOBAL MARKET REVENUE,

BY REGION, (2014-2022) ($MN) 92

TABLE 21 VASCULAR CLOSURE DEVICES GLOBAL MARKET REVENUE, BY ACCESS, (2014-2022) ($MN) 95

TABLE 22 FEMORAL VASCULAR CLOSURE DEVICES GLOBAL MARKET REVENUE,

BY REGION, (2014-2022) ($MN) 97

TABLE 23 RADIAL VASCULAR CLOSURE DEVICES GLOBAL MARKET REVENUE,

BY REGION, (2014-2022) ($MN) 100

TABLE 24 NORTH AMERICAN VASCULAR CLOSURE DEVICES MARKET REVENUE,

BY TYPE, (2014-2022) ($MN) 105

TABLE 25 NORTH AMERICAN ACTIVE APPROXIMATOR MARKET REVENUE,

BY PRODUCT, (2014-2022) ($MN) 105

TABLE 26 NORTH AMERICAN PLUGS MARKET REVENUE, BY MATERIAL,

(2014-2022) ($MN) 106

TABLE 27 NORTH AMERICAN PASSIVE APPROXIMATOR MARKET REVENUE,

BY PRODUCT, (2014-2022) ($MN) 106

TABLE 28 NORTH AMERICAN VASCULAR CLOSURE DEVICES MARKET REVENUE,

BY INTERVENTION, (2014-2022) ($MN) 107

TABLE 29 NORTH AMERICAN VASCULAR CLOSURE DEVICE MARKET REVENUE,

BY ACCESS, (2014-2022) ($MN) 107

TABLE 30 EUROPEAN VASCULAR CLOSURE DEVICES MARKET REVENUE, BY TYPE, (2014-2022) ($MN) 110

TABLE 31 EUROPEAN ACTIVE APPROXIMATOR MARKET REVENUE, BY PRODUCT, (2014-2022) ($MN) 111

TABLE 32 EUROPEAN PLUGS MARKET REVENUE, BY MATERIAL, (2014-2022) ($MN) 111

TABLE 33 EUROPEAN PASSIVE APPROXIMATOR MARKET REVENUE, BY PRODUCT, (2014-2022) ($MN) 112

TABLE 34 EUROPEAN VASCULAR CLOSURE DEVICES MARKET REVENUE,

BY INTERVENTION, (2014-2022) ($MN) 113

TABLE 35 EUROPEAN VASCULAR CLOSURE DEVICES MARKET REVENUE, BY ACCESS, (2014-2022) ($MN) 113

TABLE 36 ASIA-PACIFIC VASCULAR CLOSURE DEVICES MARKET REVENUE, BY TYPE, (2014-2022) ($MN) 116

TABLE 37 ASIA-PACIFIC ACTIVE APPROXIMATOR MARKET REVENUE, BY PRODUCT, (2014-2022) ($MN) 116

TABLE 38 ASIA-PACIFIC PLUGS MARKET REVENUE, BY MATERIAL, (2014-2022) ($MN) 117

TABLE 39 ASIA-PACIFIC PASSIVE APPROXIMATOR MARKET REVENUE, BY PRODCUT, (2014-2022) ($MN) 118

TABLE 40 ASIA-PACIFIC VASCULAR CLOSURE DEVICES MARKET REVENUE,

BY INTERVENTION, (2014-2022) ($MN) 118

TABLE 41 ASIA-PACIFIC VASCULAR CLOSURE DEVICES MARKET REVENUE,

BY ACCESS, (2014-2022) ($MN) 119

TABLE 42 ROW VASCULAR CLOSURE DEVICES MARKET REVENUE, BY TYPE,

(2014-2022) ($MN) 122

TABLE 43 ROW ACTIVE APPROXIMATOR MARKET REVENUE, BY PRODUCT,

(2014-2022) ($MN) 123

TABLE 44 ROW PLUGS MARKET REVENUE, BY MATERIAL, (2014-2022) ($MN) 123

TABLE 45 ROW PASSIVE APPROXIMATOR MARKET REVENUE, BY PRODUCT,

(2014-2022) ($MN) 124

TABLE 46 ROW VASCULAR CLOSURE DEVICES MARKET REVENUE, BY INTERVENTION, (2014-2022) ($MN) 124

TABLE 47 ROW VASCULAR CLOSURE DEVICES MARKET REVENUE, BY ACCESS,

(2014-2022) ($MN) 125

TABLE 48 MERGERS AND ACQUISITION (2011-2015) 128

TABLE 49 AGREEMENTS, PARTNERSHIPS, COLLABORATIONS & JOINT VENTURES (2012-2015) 132

TABLE 50 APPROVALS (2011-2015) 135

TABLE 51 BUSINESS EXPANSION (2011-2015) 137

TABLE 52 NEW PRODUCT LAUNCH (2011-2015) 139

TABLE 53 ABBOTT LABORATORIES: TOTAL REVENUE AND R&D EXPENSES,

(2013-2015) ($MN) 142

TABLE 54 ABBOTT LABORATORIES: TOTAL REVENUE, BY SEGMENT, (2013-2015) ($MN) 143

TABLE 55 ABBOTT LABORATORIES: TOTAL REVENUE, BY GEOGRAPHY, (2013-2015) ($MN) 144

TABLE 56 B.BRAUN MELSUNGEN AG: TOTAL REVENUE AND R&D EXPENSES,

(2012-2014) ($MN) 152

TABLE 57 B.BRAUN MELSUNGEN AG: TOTAL REVENUE, BY SEGMENT,

(2012-2014) ($MN) 153

TABLE 58 B.BRAUN MELSUNGEN AG: TOTAL REVENUE, BY GEOGRAPHY,

(2012-2014) ($MN) 154

TABLE 59 C.R.BARD INC.: TOTAL REVENUE AND R&D EXPENSES (2013-2015) ($MN) 162

TABLE 60 C.R.BARD INC: TOTAL REVENUE, BY SEGMENT, (2013-15) ($MN) 163

TABLE 61 C.R.BARD INC: TOTAL REVENUE, BY REGION, (2013-15) ($MN) 164

TABLE 62 CARDINAL HEALTH, INC.: TOTAL REVENUE AND OPERATING EXPENSES, (2013-2015) ($MN) 169

TABLE 63 CARDINAL HEALTH, INC.: TOTAL REVENUE, BY SEGMENT,

(2013-2015) ($MN) 170

TABLE 64 CARDINAL HEALTH, INC.: TOTAL REVENUE, BY GEOGRAPHY,

(2013-2015) ($MN) 171

TABLE 65 ST JUDE MEDICAL: TOTAL REVENUE AND R&D EXPENSES,

(2013-2015) ($MN) 186

TABLE 66 ST JUDE MEDICAL : TOTAL REVENUE, BY SEGMENT, (2013-2015) ($MN) 187

TABLE 67 ST.JUDE INC.: TOTAL REVENUE, BY GEOGRAPHY, (2013-2015) ($MN) 188

TABLE 68 TERUMO CORPORATION: TOTAL REVENUE AND R&D EXPENSES,

(2013-2015) ($MN) 193

TABLE 69 TERUMO CORPORATION: TOTAL REVENUE, BY SEGMENTS,

(2013-2015) ($MN) 194

TABLE 70 TERUMO CORPORATION: TOTAL REVENUE, BY GEOGRAPHY,

(2013-2015) ($MN) 195

TABLE 71 VASCULAR SOLUTIONS INC.: TOTAL REVENUE AND R&D EXPENSES, (2013-2015) ($MN) 200

TABLE 72 VASCULAR SOLUTIONS INC.: TOTAL REVENUE, BY SEGMENT,

(2013-2015) ($MN) 201

TABLE 73 VASCULAR SOLUTIONS INC.: TOTAL REVENUE, BY GEOGRAPHY,

(2013-2015) ($MN) 202

LIST OF FIGURES

FIGURE 1 VASCULAR CLOSURE DEVICE GLOBAL MARKET SHARE, BY GEOGRAPHY, (2014-22) ($MN) 17

FIGURE 2 RESEARCH METHODOLOGY: VASCULAR CLOSURE DEVICES MARKET 25

FIGURE 3 VASCULAR CLOSURE DEVICES MARKET: TOP-DOWN AND BOTTOM-UP APPROACH 26

FIGURE 4 VASCULAR CLOSURE DEVICES MARKET: FORECASTING MODEL 27

FIGURE 5 VASCULAR CLOSURE DEVICES MARKET: MARKET CRACHDOWN AND DATA TRIANGULATION 28

FIGURE 6 VASCULAR CLOSURE DEVICES MARKET: MARKET SEGMENTATION 34

FIGURE 7 MARKET DYNAMICS 36

FIGURE 8 VASCULAR CLOSURE DEVICES MARKET: PORTER’S ANALYSIS 43

FIGURE 9 VASCULAR CLOSURE DEVICE MARKET: SUPPLY CHAIN ANALYSIS 59

FIGURE 10 VASCULAR CLOSURE DEVICES GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2015 (%) 60

FIGURE 11 VASCULAR CLOSURE DEVICES MARKET: PATENT FILING BY MAJOR PLAYERS (2011-2015) 63

FIGURE 12 VASCULAR CLOSURE DEVICES GLOBAL MARKET REVENUE, BY TYPE,

(2014-2022) ($MN) 65

FIGURE 13 ACTIVE APPROXIMATOR GLOBAL MARKET REVENUE, BY PRODUCT, 2015, ($MN) 68

FIGURE 14 PASSIVE APPROXIMATOR GLOBAL MARKET REVENUE, BY PRODUCT,

(2014-2022), ($MN) 80

FIGURE 15 VASCULAR CLOSURE DEVICES GLOBAL MARKET REVENUE,

BY INTERVENTION, (2014-22) ($MN) 87

FIGURE 16 VASCULAR CLOSURE DEVICES GLOBAL MARKET REVENUE, BY ACCESS, (2015 V’S 2022) ($MN) 94

FIGURE 17 RADIAL ACCESS DEVICES GLOBAL MARKET SHARE, BY REGION, 2015, (%) 99

FIGURE 18 VASCULAR CLOSURE DEVICES GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN) (CAGR %) 102

FIGURE 19 NORTH AMERICAN VASCULAR CLOSURE DEVICES MARKET REVENUE,

BY TYPE, INTERVENTION & ACCESS, (2015 V’S 2022) ($MN) 104

FIGURE 20 EUROPEAN VASCULAR CLOSURE DEVICES MARKET REVENUE, BY TYPE, INTERVENTION & ACCESS, (2015 V’S 2022) ($MN) 109

FIGURE 21 ASIA-PACIFIC VASCULAR CLOSURE DEVICES MARKET REVENUE, BY TYPE, INTERVENTION & ACCESS, (2015 V’S 2022) ($MN) 115

FIGURE 22 ROW VASCULAR CLOSURE DEVICES MARKET REVENUE, BY TYPE, INTERVENTION & ACCESS, (2015 V’S 2022) ($MN) 121

FIGURE 23 KEY GROWTH STRATEGIES (2012-2015) 126

FIGURE 24 SWOT: ABBOTT LABORATORIES 147

FIGURE 25 SWOT: ADVANCED VASCULAR DYNAMICS 150

FIGURE 26 SWOT: B.BRAUN MELSUNGEN AG 157

FIGURE 27 SWOT: BIOTRONIK SE & CO. KG 160

FIGURE 28 SWOT: C.R.BARD INC. 167

FIGURE 29 SWOT: CARDINAL HEALTH, INC. 175

FIGURE 30 SWOT: CARDIVA MEDICALS, INC. 178

FIGURE 31 SWOT: MORRIS INNOVATIVE MEDICALS, CORP. 181

FIGURE 32 SWOT: SCION BIOMEDICAL, INC. 184

FIGURE 33 SWOT: ST.JUDE MEDICAL 191

FIGURE 34 SWOT: TERUMO CORPORATION 199

FIGURE 35 SWOT: VASCULAR SOLUTIONS INC. 204